Atossa Therapeutics, Inc. (NASDAQ:ATOS) has reported that Director Jonathan Finn has purchased shares of the company’s common stock. The transaction, dated April 10, 2024, involved the acquisition of 25,000 shares at an average price of $1.77 per share, totaling $44,250.
The recent purchase by Finn reflects a vote of confidence in the pharmaceutical company, which specializes in the development of novel therapeutics. This transaction saw shares bought at prices ranging from $1.74 to $1.78, showcasing a modest fluctuation in the purchase price during the buying period.
Investors often monitor insider transactions such as these for insights into the perspectives of high-level executives and directors within the company. The accumulation of shares by an insider can signal their belief in the firm's potential or undervaluation.
Following the transaction, Finn now directly owns 25,000 shares in Atossa Therapeutics. The company, incorporated in Delaware and based in Seattle, Washington, is known for its work in the pharmaceutical preparations sector.
Atossa Therapeutics continues to operate in its field, aiming to bring innovative solutions to market. The insider activity reported may draw investor attention as they assess the implications of such stock purchases by company directors.
InvestingPro Insights
As Atossa Therapeutics, Inc. (NASDAQ:ATOS) garners attention with insider stock purchases, real-time data from InvestingPro provides a deeper financial perspective on the company. With a market capitalization of approximately $221.79 million, Atossa Therapeutics presents an interesting case for investors. Notably, the company's Price to Earnings (P/E) Ratio stands at -7.41, reflecting its current earnings challenges. The adjusted P/E ratio for the last twelve months as of Q4 2023 is slightly more pronounced at -8.06.
InvestingPro Tips highlight that Atossa Therapeutics holds more cash than debt on its balance sheet, which is a positive sign of financial stability. However, the company has not been profitable over the last twelve months, with an Operating Income of -$31.38 million and an EBITDA of -$31.35 million for the same period. This aligns with the analyst anticipation that the company will not be profitable this year.
Despite these challenges, the company has experienced a strong return over the last month, with a 45.83% increase, and an even more impressive three-month price total return of 93.78%. Over the last six months, the price uptick is a substantial 150.0%. This performance could be part of what inspired Director Jonathan Finn's recent investment in the company's stock.
For those interested in further insights and metrics, InvestingPro offers additional tips that can help investors make more informed decisions. With a total of 10 more InvestingPro Tips available for Atossa Therapeutics, investors can use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, providing access to comprehensive analysis and data that can enrich investment strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.